Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: The Swiss HIV Cohort Study

HIV Medicine

Volumn 10, Issue 7, 2009, Pages 407-416

  Weber, R ^a,j   Huber, M ^a   Rickenbach, M ^b,i   Furrer, H ^c,h   Elzi, L ^b,d   Hirschel, B ^e,i   Cavassini, M ^b,b   Bernasconi, E ^b,f   Schmid, P ^g,j   Ledergerber, B ^a,i   Battegay, M ^b   Boni J ^b   Bucher, H C ^b   Burgisser Ph ^b   Calmy, A ^b   Cattacin, S ^b   Dubs, R ^b   Egger, M ^b   Fischer, M ^b   Flepp, M ^b   Fontana, A ^b   Francioli, P ^b   Fux, C ^j   Gorgievski, M ^j   Gunthard H ^j   Hirsch, H ⁱ   Hosli I ⁱ   Kahlert, Ch ⁱ   Kaiser, L ⁱ   Karrer, U ⁱ   Kind, C ⁱ   Klimkait, Th ⁱ   Martinetti, G ⁱ   Martinez, B ⁱ   Muller N ⁱ   Nadal, D ⁱ   Opravil, M ⁱ   Paccaud, F ⁱ   Pantaleo, G ⁱ   Rauch, A ⁱ   Regenass, S ⁱ   Rudin, C ^j   Schultze, D ^j   Schupbach J ^j   Speck, R ^j   Taffe P ^j   Telenti, A ^j   Trkola, A ^j   Vernazza, P ^j   Yerly, S ^j   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY HOSPITAL   (Switzerland)

^f REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h Clinical and Laboratory Committee

ⁱ Data Centre   (Switzerland)

^j Data Centre ^*

more..

Author keywords

Antiretroviral therapy; Cohort study; HIV infection; Injecting drug use; Opiate substitution

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SWITZERLAND; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; RNA, VIRAL; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; SWITZERLAND; TREATMENT OUTCOME;

EID: 67650699246     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00701.x     Document Type: Article

References (56)

1. UNAIDS. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO): AIDS epidemic update 2007. Available at http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/ EpiUpdArchive/2007/ accessed 1 March 2009.
2. Mathers BM, Degenhardt L, Phillips B et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: A systematic review. Lancet 2008; 372: 1733-1745.
3. Wood E, Kerr T, Tyndall MW, Montaner JS. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS 2008; 22: 1247-1256.
4. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27: 251-259.
5. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The MANIF 2000 Study Group. AIDS 2000; 14: 151-155.
6. Stein MD, Rich JD, Maksad J et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: Effect of ongoing illicit drug use. Am J Drug Alcohol Abuse 2000; 26: 195-205.
7. Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr 2003; 32: 522-526.
8. McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: The importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis 2005; 41(Suppl. 1): S89-S95.
9. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002; 36: 1598-1613.
10. Strathdee SA, Palepu A, Cornelisse PG et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280: 547-549.
11. Wood E, Hogg RS, Kerr T, Palepu A, Zhang R, Montaner JS. Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naïve HIV-infected injection drug users. AIDS 2005; 19: 837-839.
12. Celentano DD, Galai N, Sethi AK et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001; 15: 1707-1715.
13. Murri R, Ammassari A, De Luca A, Cingolani A, Antinori A, Ortona L. Use of antiretroviral therapy by intravenous drug users with HIV. JAMA 1999; 281: 700-701.
14. Ding L, Landon BE, Wilson IB, Wong MD, Shapiro MF, Cleary PD. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med 2005; 165: 618-623.
15. Wood E, Montaner JS. [Commentary] Antiretroviral therapy: A key part of the public health response to injection drug use. Addiction 2008; 103: 660-661.
16. Sabin CA, Smith CJ, Youle M et al. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006; 20: 67-71.
17. Sterne JA, Hernan MA, Ledergerber B et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: A prospective cohort study. Lancet 2005; 366: 378-384.
18. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: A longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006; 163: 412-420.
19. Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano DD. Longitudinal patterns of drug injection behavior in the ALIVE Study Cohort, 1988-2000: Description and determinants. Am J Epidemiol 2003; 158: 695-704.
20. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353: 863-868.
21. Glass TR, De Geest S, Weber R et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2006; 41: 385-392.
22. Glass TR, De Geest S, Hirschel B et al. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther 2008; 13: 77-85.
23. Weber R, Ledergerber B, Opravil M, Siegenthaler W, Luthy R. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. BMJ 1990; 301: 1362-1365.
24. Peterson PK, Gekker G, Chao CC, Schut R, Molitor TW, Balfour HH Jr. Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures. Involvement of transforming growth factor-beta. J Immunol 1991; 146: 81-84.
25. Nair MP, Chadha KC, Hewitt RG, Mahajan S, Sweet A, Schwartz SA. Cocaine differentially modulates chemokine production by mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol 2000; 7: 96-100.
26. Kapadia F, Vlahov D, Donahoe RM, Friedland G. The role of substance abuse in HIV disease progression: Reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis 2005; 41: 1027-1034.
27. Pellegrino T, Bayer BM. In vivo effects of cocaine on immune cell function. J Neuroimmunol 1998; 83: 139-147.
28. Pellegrino TC, Dunn KL, Bayer BM. Mechanisms of cocaine-induced decreases in immune cell function. Int Immunopharmacol 2001; 1: 665-675.
29. Novick DM, Ochshorn M, Kreek MJ. In vivo and in vitro studies of opiates and cellular immunity in narcotic addicts. Adv Exp Med Biol 1991; 288: 159-170.
30. Madden JJ, Wang Y, Lankford-Turner P, Donahoe RM. Does reduced DNA repair capacity play a role in HIV infection and progression in the lymphocytes of opiate addicts? J Acquir Immune Defic Syndr 2002; 31(Suppl. 2): S78-S83.
31. Ferreros I, Lumbreras B, Hurtado I, Perez-Hoyos S, Hernandez-Aguado I. The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users. Addiction 2008; 103: 651-659.
32. Muga R, Langohr K, Tor J et al. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs. Clin Infect Dis 2007; 45: 370-376.
33. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001; 15: 1115-1123.
34. FOPH. Swiss Federal Office for Public Health: Federal measures to reduce the problems of drug abuse. FOPH basic document 341f, Bern 1991.
35. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. Lancet 2001; 358: 1417-1423.
36. Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 2004; 35: 46-51.
37. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16: 767-774.
38. Ledergerber B, Egger M, Rickenbach M, Weber R. Poverty and prognosis of HIV infection in Switzerland. Swiss HIV Cohort Study. AIDS 1998; 12: 1933-1934.
39. Simoni JM, Frick PA, Huang B. A longitudinal evaluation of a social support model of medication adherence among HIV-positive men and women on antiretroviral therapy. Health Psychol 2006; 25: 74-81.
40. Ickovics JR, Hamburger ME, Vlahov D et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001; 285: 1466-1474.
41. Bouhnik AD, Preau M, Vincent E et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther 2005; 10: 53-61.
42. Sorensen HJ, Jepsen PW, Haastrup S, Juel K. Drug-use pattern, comorbid psychosis and mortality in people with a history of opioid addiction. Acta Psychiatr Scand 2005; 111: 244-249.
43. Lloyd-Smith E, Brodkin E, Wood E et al. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 2006; 20: 445-450.
44. Copeland L, Budd J, Robertson JR, Elton RA. Changing patterns in causes of death in a cohort of injecting drug users, 1980-2001. Arch Intern Med 2004; 164: 1214-1220.
45. Ewings FM, Bhaskaran K, McLean K et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS 2008; 22: 89-95.
46. Lucas GM, Weidle PJ, Hader S, Moore RD. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: A nonrandomized comparative study. Clin Infect Dis 2004; 38(Suppl. 5): S409-S413.
47. Palepu A, Tyndall MW, Joy R et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: The role of methadone maintenance therapy. Drug Alcohol Depend 2006; 84: 188-194.
48. Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: A prospective, randomized, controlled trial. Clin Infect Dis 2007; 45: 770-778.
49. Dronda F, Zamora J, Moreno S et al. CD4 cell recovery during successful antiretroviral therapy in naïve HIV-infected patients: The role of intravenous drug use. AIDS 2004; 18: 2210-2212.
50. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study. Lancet 2000; 356: 1800-1805.
51. Cofrancesco J Jr, Scherzer R, Tien PC et al. Illicit drug use and HIV treatment outcomes in a US cohort. AIDS 2008; 22: 357-365.
52. Bale RN, van Stone WW, Engelsing TM, Zarcone VP Jr, Kuldan JM. The validity of self-reported heroin use. Int J Addict 1981; 16: 1387-1398.
53. Dobler-Mikola A, Hattenschwiler J, Meili D, Beck T, Boni E, Modestin J. Patterns of heroin, cocaine, and alcohol abuse during long-term methadone maintenance treatment. J Subst Abuse Treat 2005; 29: 259-265.
54. Jaggy C, von Overbeck J, Ledergerber B et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362: 877-878.
55. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284: 1689-1695.
56. Smit C, Lindenburg K, Geskus RB, Brinkman K, Coutinho RA, Prins M. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: A prospective cohort study of sexual risk and injecting behaviour. Addiction 2006; 101: 433-440.